company background image
BGNE

BeiGene NasdaqGS:BGNE Stock Report

Last Price

US$183.13

Market Cap

US$19.2b

7D

0.2%

1Y

-4.4%

Updated

29 Nov, 2023

Data

Company Financials +

BGNE Stock Overview

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide.

BGNE fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for BGNE from our risk checks.

BeiGene, Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BeiGene
Historical stock prices
Current Share PriceUS$183.13
52 Week HighUS$280.62
52 Week LowUS$156.56
Beta0.63
1 Month Change-1.86%
3 Month Change-11.77%
1 Year Change-4.43%
3 Year Change-19.33%
5 Year Change24.44%
Change since IPO546.65%

Recent News & Updates

Recent updates

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Oct 16
Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Jul 11
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Jun 19
Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

Apr 17
Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Mar 24
A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?

Dec 07
Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?

BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential

Oct 13

EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa

Sep 16

BeiGene, McKesson team up to develop data, tools for US community oncology care

Aug 15

Novartis/BeiGene's tislelizumab matches Bayer's Nexavar in survival benefit for liver cancer patients in trial

Aug 09

FDA defers action on Novartis/BeiGene's tislelizumab for esophagus cancer citing inspection woes

Jul 14

BeiGene in pact with InnoRNA to develop messenger RNA-based therapies

Jul 06

Health Check: How Prudently Does BeiGene (NASDAQ:BGNE) Use Debt?

Jun 30
Health Check: How Prudently Does BeiGene (NASDAQ:BGNE) Use Debt?

Shareholder Returns

BGNEUS BiotechsUS Market
7D0.2%0.5%0.09%
1Y-4.4%-8.9%10.4%

Return vs Industry: BGNE exceeded the US Biotechs industry which returned -7.1% over the past year.

Return vs Market: BGNE underperformed the US Market which returned 13.3% over the past year.

Price Volatility

Is BGNE's price volatile compared to industry and market?
BGNE volatility
BGNE Average Weekly Movement7.0%
Biotechs Industry Average Movement11.2%
Market Average Movement6.0%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.9%

Stable Share Price: BGNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: BGNE's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201010,000John Oylerhttps://www.beigene.com

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology.

BeiGene, Ltd. Fundamentals Summary

How do BeiGene's earnings and revenue compare to its market cap?
BGNE fundamental statistics
Market CapUS$19.24b
Earnings (TTM)-US$959.49m
Revenue (TTM)US$2.20b

8.6x

P/S Ratio

-19.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BGNE income statement (TTM)
RevenueUS$2.20b
Cost of RevenueUS$2.08b
Gross ProfitUS$126.23m
Other ExpensesUS$1.09b
Earnings-US$959.49m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-9.22
Gross Margin5.73%
Net Profit Margin-43.52%
Debt/Equity Ratio14.1%

How did BGNE perform over the long term?

See historical performance and comparison